William Maughan
Stock Analyst at Canaccord Genuity
(3.01)
# 1,474
Out of 4,761 analysts
24
Total ratings
58.33%
Success rate
56.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $120.01 | +42.85% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $5.72 | +214.69% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $15.74 | +166.84% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $4.99 | +220.64% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $11.66 | +414.58% | 1 | Jul 6, 2022 |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $120.01
Upside: +42.85%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $5.72
Upside: +214.69%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $15.74
Upside: +166.84%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $4.99
Upside: +220.64%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $11.66
Upside: +414.58%